6 recruiting, 5 completed, 4 not yet recruiting, 3 active not recruiting. 7 Phase 2, 3 Not applicable, 2 Phase 1, 2 Phase 3.
Follow Polycythemia Vera (PV): new trials by email Literature Review of Polycythemia Vera (PV) trials Research Report on Polycythemia Vera (PV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ropeg-Interferon in People With Polycythemia Vera Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2026-10-30 | 2026-10-21 |
| Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers ZE74-0282 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Not yet recruiting | Eilean Therapeutics | 60 | 2026-05-15 | 2026-04-14 |
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 100 | 2026-04-29 | 2026-10-01 |
| A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV Gecacitinib Hydrochloride Tablets；Pegylated interferon alfa-2b - Polycythemia Vera (PV) | Not applicable | Recruiting | Duan Minghui | 30 | 2026-04-02 | 2026-06-24 |
| Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera Research samples blood viscosity and viscoelasticity: - Polycythemia, Polycythemia Vera (PV) | Not applicable | Not yet recruiting | Hospices Civils de Lyon | 54 | 2026-01-01 | 2026-01-15 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg - Polycythemia Vera (PV) | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 60 | 2025-09-23 | 2026-08-14 |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) DISC-3405 - Polycythemia Vera (PV) | Phase 2 | Active not recruiting | Disc Medicine, Inc | 60 | 2025-08-12 | 2026-07-31 |
| EVAluation of Erythrocytosis PRospEctive Cohort STudy Erythrocytosis, Polycythemia | Not yet recruiting | Cyrus Hsia | 1500 | 2025-02-01 | 2025-01-21 | |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| A Study to Evaluate P1101 in Japanese PV Patients P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 3 | Completed | PharmaEssentia Japan K.K. | 21 | 2023-10-17 | 2024-11-08 |
| Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms Essential Thrombocythemia (ET), Myelofibrosis (MF) | Active not recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 110 | 2022-02-15 | 2025-01-29 | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients P1101 (Ropeginterferon alfa-2b) - Polycythemia Vera (PV) | Phase 3 | Recruiting | PharmaEssentia Japan K.K. | 67 | 2021-01-19 | 2024-11-08 |
| Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. Ruxolitinib - Polycythemia Vera (PV) | Completed | Novartis Pharmaceuticals | 1576 | 2020-11-27 | 2022-07-05 | |
| Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 2 | Completed | PharmaEssentia Japan K.K. | 29 | 2019-12-20 | 2025-09-15 |
| The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Ruxolitinib, BAT - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Active not recruiting | RWTH Aachen University | 207 | 2015-10-01 | 2026-08-13 |
| Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms Upper gastrointestinal endoscopy and Doppler ultrasound - Myeloproliferative Neoplasms (MPN), Polycythemia Vera (PV) | Not applicable | Completed | University Health Network, Toronto | 102 | 2013-05-01 | 2023-07-21 |
| Managed Access Programs for INC424, Ruxolitinib Ruxolitinib - Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) | Available | Novartis Pharmaceuticals | 2025-11-18 |
Polycythemia Vera (19) · Primary Myelofibrosis (8) · Myeloproliferative Disorders (7) · Thrombocythemia, Essential (6) · Polycythemia (2) · Blast Crisis (1) · Bone Marrow Neoplasms (1) · Disease (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Polycythemia, primary familial and congenital (1) · Rare Diseases (1) · Venous Thromboembolism (1)
Bone Marrow Diseases (19) · Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Neoplasms (19) · Neoplasms by Site (19) · Bone Marrow Neoplasms (18) · Hematologic Neoplasms (18) · Myeloproliferative Disorders (12) · Blood Coagulation Disorders (6) · Blood Platelet Disorders (6) · Hemorrhagic Disorders (6) · Thrombocytosis (6) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Carcinogenesis (1)
Aspirin (3) · ruxolitinib (3) · Phlebotomy (2) · Drug Evaluation (1) · Endoscopy, Digestive System (1) · Methotrexate (1) · Spectroscopy, Near-Infrared (1) · Tablets (1) · apixaban (1)
PharmaEssentia Japan K.K. (3) · Novartis Pharmaceuticals (2) · Chengdu Zenitar Biomedical Technology Co., Ltd (1) · Cyrus Hsia (1) · Disc Medicine, Inc (1) · Duan Minghui (1) · Eilean Therapeutics (1) · Hospices Civils de Lyon (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Icahn School of Medicine at Mount Sinai (1) · MPN Research Foundation (1) · Memorial Sloan Kettering Cancer Center (1) · Ottawa Hospital Research Institute (1) · Prelude Therapeutics Incorporated (1) · RWTH Aachen University (1)
United States (6) · Canada (3) · Japan (3) · China (2) · France (2) · Australia (1) · Germany (1) · Italy (1) · Spain (1)
Raajit Rampal, MD, PhD (2) · Aurelien Delluc, MD, PhD (1) · John Mascarenhas (1) · Keita Kirito, MD (1) · Lei Zhang, Doctor (1) · Lucia Catani, MD (1) · Miriam Kimpton, MD (1) · Steffen Koschmieder, Prof. Dr. (1) · Ting Niu, Doctor (1) · Vikas Gupta, MD, FRCP (1) · Wei Yang, Doctor (1) · Will Savage, MD PhD (1)